153 related articles for article (PubMed ID: 36819558)
21. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
22. CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma.
Martín-Ezquerra G; Salgado R; Toll A; Baró T; Mojal S; Yébenes M; Garcia-Muret MP; Solé F; Quitllet FA; Espinet B; Pujol RM
Histol Histopathol; 2011 Jan; 26(1):71-7. PubMed ID: 21117028
[TBL] [Abstract][Full Text] [Related]
23. Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma.
Xu J; Sun Y; Jiang J; Xu Z; Li J; Xu T; Liu P
Front Immunol; 2020; 11():1292. PubMed ID: 32760394
[TBL] [Abstract][Full Text] [Related]
24. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
25. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
[TBL] [Abstract][Full Text] [Related]
26. [Clinical Analysis of Patients with MGUS, Primary Light Chain Amyloidosis, Multiple Myeloma or Multiple Myeloma with Concurrent Amyloidosis].
Mao XH; Deng SH; Sui WW; Fu MW; Liu JH; Fan HS; Zou DH; Zhao YZ; Qiu LG; An G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):812-818. PubMed ID: 34105477
[TBL] [Abstract][Full Text] [Related]
27. ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.
Wu C; Yang T; Liu Y; Lu Y; Yang Y; Liu X; Liu X; Ye L; Sun Y; Wang X; Li Q; Yang P; Yu X; Gao S; Kumar S; Jin F; Dai Y; Li W
Cancer Med; 2018 Aug; 7(8):3899-3911. PubMed ID: 29926531
[TBL] [Abstract][Full Text] [Related]
28. [Application of CD138 Immunomagnetic Bead Sorting Combined with Fluorescence in Situ Hybridization in Multiple Myeloma].
Li QZ; Tan K; Liu YX; Huang H; Zhang Y; Chen HM; Chen ZZ; Zhu ZW; Yang BH; Hu GY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1496-1500. PubMed ID: 36208255
[TBL] [Abstract][Full Text] [Related]
29. Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.
Liu X; Jia S; Chu Y; Tian B; Gao Y; Zhang C; Zheng Y; Jia W; Liu X; Yuan R; Zhang N; Feng J; Dong H; Xin X; Chang Z; Cao Z; Tang H; Gao G
Front Oncol; 2022; 12():938550. PubMed ID: 36185185
[TBL] [Abstract][Full Text] [Related]
30. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells.
Reid RJ; Du X; Sunjevaric I; Rayannavar V; Dittmar J; Bryant E; Maurer M; Rothstein R
Genetics; 2016 Oct; 204(2):807-819. PubMed ID: 27558135
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of 1q21 Gain in Multiple Myeloma.
Chen D; Zhou D; Xu J; Zhou R; Ouyang J; Chen B
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e159-e164. PubMed ID: 30685183
[TBL] [Abstract][Full Text] [Related]
32. Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.
Lim AS; Krishnan S; Lim TH; See K; Ng YJ; Tan YM; Choo N; Lau LC; Tien SL; Ma J; Tan D
Indian J Hematol Blood Transfus; 2014 Dec; 30(4):253-8. PubMed ID: 25435723
[TBL] [Abstract][Full Text] [Related]
33. [Correlation between Expression Patterns of CD117/CD200 in Plasma Cells and Molecular Genetic Prognostic Parameters in Multiple Myeloma].
Wang P; Wang XD; Liu L; Chen X; Liu F; Zhao SS; Yang H; Qiu HR; Guo R; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1415-1420. PubMed ID: 37846693
[TBL] [Abstract][Full Text] [Related]
34. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
35. CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour.
Salgado R; Toll A; Alameda F; Baró T; Martín-Ezquerra G; Sanmartín O; Martorell-Calatayud A; Salido M; Almenar S; Solé F; Pujol RM; Espinet B
Genes Chromosomes Cancer; 2010 Nov; 49(11):1054-61. PubMed ID: 20737481
[TBL] [Abstract][Full Text] [Related]
36. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.
Yu W; Guo R; Qu X; Qiu H; Li J; Zhang R; Chen L
Onco Targets Ther; 2016; 9():295-302. PubMed ID: 26834489
[TBL] [Abstract][Full Text] [Related]
37. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
40. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]